Ciba Corning Diagnostics
This article was originally published in The Gray Sheet
Executive SummaryLaunches ACS prostate-specific antigen test for prostate cancer management Sept. 22. FDA approved the firm's premarket approval application for the test Aug. 23. The direct chemiluminescent immunoassay will be sold in the U.S. by 130 direct sales reps at a list price of $3,780 for a kit of 300 tests. Ciba Corning joins Hybritech, Tosoh Medics, and Abbott in marketing a PSA test in the U.S. The company plans to file additional data with FDA to support use of the assay to aid in the diagnosis of prostate cancer. Hybritech's Tandem recently became the first PSA test to gain FDA approval as a diagnostic aid ("The Gray Sheet" Sept. 5, p. 13)
You may also be interested in...
TTS Pharma CEO Mark Tucker discusses his ambition to bring a legal CBD oil to the UK market, following the recent submission of a European Union novel food application.
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.